mPEG-b-PCL-Based Nanoformulations of Aziridine-Functionalized 1,3,5-Triazine Derivative for Cancer Treatment
- 1Institute of Chemistry, Saint-Petersburg State University, Universitetskiy Pr. 26, 198504 St. Petersburg, Russia
- 2Branch of Petersburg Nuclear Physics Institute Named by B.P. Konstantinov of National Research Center “Kurchatov Institute”—Institute of Macromolecular Compounds, Bolshoi Pr. 31, 199004 St. Petersburg, Russia
- 3NMRC Institute of Oncology Named After N.N. Petrov, Leningradskaya Str. 68, Pesochny, 197758 St. Petersburg, Russia
Abstract
Developing nanoformulations of antitumor drugs represents a critical priority in addressing key challenges of free drug administration such as low therapeutic efficacy, poor bioavailability, and severe side effects, including high systemic toxicity. In this study, mPEG-b-PCL block copolymers of different molecular weights were synthesized and applied to develop nanoformulations of the antitumor aziridine-functionalized 1,3,5-triazine derivative, dioxadet (DOD) via nanoprecipitation. The resulting DOD-loaded nanoparticles exhibited optimal characteristics for intravenous administration, and high encapsulation efficiency. The effect of mPEG-b-PCL molecular weight on drug encapsulation and release was investigated, and the results were elucidated through computational analysis of the molecular binding mechanism between DOD and PCL. Release profiles showed a sustained biphasic pattern. Determination of DOD concentration in blood of healthy rats indicated that the nanoformulation extended DOD’s circulation time. The empty nanoparticles were well-tolerated by both normal and cancer cells. The nanoformulation maintained inhibitory activity against A549 cells with an IC50, comparable to that of free DOD. The antitumor efficacy and reduced toxicity of the optimized nanoformulation were demonstrated in mice using two ascitic tumor models (Ehrlich ascites carcinoma and L1210 lymphoid leukemia) and one solid tumor model (Lewis lung epidermoid carcinoma) with the greatest therapeutic effect observed against the solid tumor.
Related
- Novel 2,4-Pyrimidinediamine Derivative as Potent EGFR Inhibitor for NSCLC Treatment
- Direct Access to α-Chiral Amino-Oxetanes via Boron-Assisted Aziridine Ring-Opening
- Anion‐Receptive Triazine‐Centered Azobenzene Trimers
- A novel magnetic N-rich covalent triazine framework-copper(ii) complex as an efficient nanocatalyst for Ullmann coupling.
- From Design to Synergy: Triazine-Triazole Hybrids as Anti-Breast Cancer Leads Targeting Survival and Invasion Pathways for Augmenting Lapatinib Efficacy.
BibTeX
@article{bagaeva2026mpegbpclbased,
title = {{mPEG-b-PCL-Based Nanoformulations of Aziridine-Functionalized 1,3,5-Triazine Derivative for Cancer Treatment}},
author = {Irina Bagaeva and Ekaterina Sinitsyna and Yuliia Zmitrichenko and Gregorii Tochilnikov and Elena Tupikina and Sergei Silonov and Mikhail Orlov and Viktor Korzhikov-Vlakh and Evgenia Korzhikova-Vlakh},
journal = {Polymers},
year = {2026},
month = oct,
doi = {10.3390/polym18192409},
url = {https://europepmc.org/article/PMC/PMC13667229},
note = {CC BY},
}
RIS
TY - JOUR
TI - mPEG-b-PCL-Based Nanoformulations of Aziridine-Functionalized 1,3,5-Triazine Derivative for Cancer Treatment
AU - Irina Bagaeva
AU - Ekaterina Sinitsyna
AU - Yuliia Zmitrichenko
AU - Gregorii Tochilnikov
AU - Elena Tupikina
AU - Sergei Silonov
AU - Mikhail Orlov
AU - Viktor Korzhikov-Vlakh
AU - Evgenia Korzhikova-Vlakh
PY - 2026
DA - 2026/10/01
JO - Polymers
DO - 10.3390/polym18192409
UR - https://europepmc.org/article/PMC/PMC13667229
AB - Developing nanoformulations of antitumor drugs represents a critical priority in addressing key challenges of free drug administration such as low therapeutic efficacy, poor bioavailability, and severe side effects, including high systemic toxicity. In this study, mPEG-b-PCL block copolymers of different molecular weights were synthesized and applied to develop nanoformulations of the antitumor aziridine-functionalized 1,3,5-triazine derivative, dioxadet (DOD) via nanoprecipitation. The resulting DOD-loaded nanoparticles exhibited optimal characteristics for intravenous administration, and high encapsulation efficiency. The effect of mPEG-b-PCL molecular weight on drug encapsulation and release was investigated, and the results were elucidated through computational analysis of the molecular binding mechanism between DOD and PCL. Release profiles showed a sustained biphasic pattern. Determination of DOD concentration in blood of healthy rats indicated that the nanoformulation extended DOD’s circulation time. The empty nanoparticles were well-tolerated by both normal and cancer cells. The nanoformulation maintained inhibitory activity against A549 cells with an IC50, comparable to that of free DOD. The antitumor efficacy and reduced toxicity of the optimized nanoformulation were demonstrated in mice using two ascitic tumor models (Ehrlich ascites carcinoma and L1210 lymphoid leukemia) and one solid tumor model (Lewis lung epidermoid carcinoma) with the greatest therapeutic effect observed against the solid tumor.
SN - 2073-4360
ER -